Clinician ordering practices for voriconazole therapeutic drug monitoring: Experiences of a referral laboratory

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 661-664

  Miyakis, Spiros ^a   Van Hal, Sebastiaan J ^a   Solvag, Carl Jacob S ^a   Ray, John ^a   Marriott, Deborah ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

invasive fungal infection; serum concentration; test ordering; therapeutic drug monitoring; voriconazole

Indexed keywords

VORICONAZOLE;

ADULT; ARTICLE; AUSTRALIA; CLINICAL LABORATORY; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AUSTRALIA; DRUG MONITORING; FEMALE; HUMANS; LABORATORIES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINES; REFERRAL AND CONSULTATION; TRIAZOLES;

EID: 77957257779     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ea3de6     Document Type: Article

References (15)

1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415. (Pubitemid 34851833)
2. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360.
3. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
4. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570-1572.
5. Miyakis S, van Hal SJ, Ray J, et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16:927-933.
6. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
7. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532-1535.
8. Barr JT, Schumacher GE. The Total Testing Process Applied to Therapeutic Drug Monitoring. Norwalk, CT: Appleton & Lange; 1995.
9. Worth LJ, Blyth CC, Booth DL, et al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern Med J. 2008;38:521-537.
10. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother. 2007;51:137-143.
11. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35:509-513.
12. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403-411.
13. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
14. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235-243.
15. Walko CM, McLeod HL. Will we ever be ready for blood level-guided therapy? J Clin Oncol. 2008;26:2078-2079.